^
Association details:
| Biomarker: | KRAS G12D + Chr del(9)(p21) |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
2960 - A novel mouse model of pancreatic cancer reveals new insights into cell cycle deregulation
Published date:
03/10/2021
Excerpt:
...we have developed a novel genetically engineered mouse model (GEMM) of PDA which combines loss of the orthologous murine 9p21 region (4qC4) with activated KRAS [Pdx-Cre; LSL-KrasG12D; 9p21L/L (K9C)],.. K9C derived cell lines are responsive to Pfizer’s first-in class CDK2/4/6 selective inhibitor while displaying de novo resistance to CDK4/6 inhibitor Palbociclib.
